Pharmaceuticals (Basel, Switzerland)
Pharmacogenomics of Sorafenib in Hepatocellular Carcinoma (HCC): A LncRNA-Expression Guided Approach Using UCA1 and MALAT1 for Personalizing Therapy in a 154-Patient Cohort.
Mahmoud Nazih, Imam Waked, Shimaa Abdelsattar, Hiba S Al-Amodi, Hala F M Kamel, Muhammad Mahmoud Attia, Ahmed I Khoder, Sahar Badr Hassan, Mohamed Mahmoud Abdel-Latif
Published: 202510.3390/ph19010070
Abstract
Background/Objectives: Hepatocellular carcinoma (HCC) presents limited therapeutic options for advanced disease, and sorafenib therapy is hampered by significant interpatient heterogeneity in response. This necessitates biomarker-guided strategies to…
Preview only. Read the full abstract at the source